Zahed Subhan

Presently Chief Executive Officer and co-founder of Marillion Pharmaceuticals Inc, Dr. Subhan has 25 years experience in the pharmaceutical and biotechnology industries spanning roles in research, clinical development, sales, marketing and business development, including managerial positions with Sanofi-Aventis, GlaxoSmithKline, Merck, the Dupont-Merck Pharmaceutical Company (now part of Bristol-Myers Squibb), Gemini Genomics (now Sequenom, Inc) and Locus Pharmaceuticals. Dr. Subhan was also previously Chief Executive Officer of Nuevolution A/S based in Copenhagen, Denmark. During his career, Dr. Subhan has been instrumental in establishing more than 40 collaborations and co-operative agreements with major pharmaceutical and biotech companies, including licensing, co-marketing, co-promotion and acquisition transactions valued in excess of $600MM. Dr Subhan has also been responsible for the successful launches of flagship drugs in major markets, including Imitrex®, Celexa®, Prinivil®/Zestril®, Sinemet CR® and Viazem®/Tiazac®.

Dr. Subhan holds a PhD in Pharmacology from the University of Leeds, an MBA from the University of Bradford and a Law degree from the University of London.